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I. INTRODUCTION
General hospitals and medical clinics have converted to smoke-free buildings 
and are increasingly converting their premises to smoke-free as a component of health 
promotion.1  Accreditation requirements by the Joint Commission on Accreditation 
of Healthcare Organizations (“JCAHO”) prompted the nationwide conversion to 
smoke-free medical facility buildings in 1992.2  Increasingly, state legislatures are 
passing state-wide smoking bans for workplaces, restaurants, and bars with no ex-
emptions for separately ventilated rooms.3  Despite this widespread trend toward 
smoke-free public buildings and workplaces, many state and public psychiatric treat-
ment facilities continue to support tobacco use on their premises by patients, staff, 
and visitors.4  Most state psychiatric facilities have moved smoking outdoors while 
some facilities even allow indoor smoking.5  Outdoor smoking allows non-smoking 
patients and staff to avoid the dangers of environmental tobacco smoke and qualifies 
these treatment facilities for JCAHO accreditation.6  This paper will examine the 
historic debate over maintaining tobacco availability within psychiatric facilities. 
Because opposition to tobacco-free state psychiatric facility grounds continues to 
exist, this author argues that the legislative process is necessary to make this change 
in a fair, effective, and efficient manner.
Advocates for keeping tobacco available base their arguments on a patient’s right 
to choose to smoke and on the historic, and commonly held, belief that forcing pa-
tients with mental illness to forego smoking—even while providing nicotine 
replacement—creates a potential harm.7  Some mental health professionals believe 
that preventing patients from smoking will likely create confrontations, agitation, 
1. Richard D. Hurt et al., The Making of a Smoke-Free Medical Center, 261 JAMA 95, 95 (1989); see also 
Anne M. Joseph et al., Determinants of Compliance with a National Smoke-Free Hospital Standard, 274 
JAMA 491, 492 (1995) (“Smoke-free hospital policies are designed to minimize patient, employee, and 
visitor exposure to secondhand smoke, encourage patients and employees to quit smoking and set an 
example for the community of institutional policies that ref lect scientific knowledge about the health 
risks of smoking.”).
2. See Joint Commission on Accreditation of Healthcare Organizations, Comprehensive 
Accreditation Manual for Hospitals: The Official Handbook (2005) (referring to Standard 
EC 1.30, which requires that “[t]he hospital develops and implements a policy to prohibit smoking 
except in specified circumstances”). 
3. As of October 2, 2008, twenty-one states, including Puerto Rico, do not allow smoking in bars, and 
twenty-seven states, including Puerto Rico, do not allow smoking in restaurants.  See Americans for 
Nonsmokers’ Rights Foundation, States, Commonwealths, and Municipalities with 100% Smokefree Laws 
in Workplaces, Restaurants, and Bars (Oct. 2, 2008), http://www.no-smoke.org/pdf/100ordlist.pdf. 
4. State or public psychiatric facilities are operated and funded by states as agencies to provide treatment 
for mentally ill or chemically dependent citizens who are frequently involuntarily hospitalized according 
to state civil commitment statutory law.
5. See Kathleen M. Monihan et al., A Comparative Analysis of Smoking Policies Among State Psychiatric 
Hospitals, June 2006, http://www.nri-inc.org/reports_pubs/2006/SmokingPoliciesProceduresReport2006.
pdf.
6. See id.
7. See Ilya Kagan et al., Patient Rights and Law: Tobacco Smoking in Psychiatric Wards and the Israeli 
Prevention of Smoking Act, 11 Nursing Ethics 472 (2004); cf. Nat’l Ass’n State Mental Health 
Program Dirs., Technical Report on Smoking Policy and Treatment in State 
Operated Psychiatric Facilities 1, at 10 ( Joseph Parks & Peggy Jewell eds., 2006), 
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and even violence.8  Smoking inside medical facilities, such as within locked psychi-
atric wards, is viewed as a means for patients to relax in times of distress, to ease 
their boredom, and to promote social interaction.9  Mental health professionals advo-
cate for tobacco availability based on the hypothetical benefits of smoking on 
symptoms of schizophrenia, and the potential benefits of nicotine on cognitive func-
tioning.10  Mental health professionals are trained to empathize with patients’ 
suffering.  This process of empathy involves an attempt to understand and imagina-
tively enter into another person’s feelings.  Thus, the cravings to use tobacco 
experienced by patients likely brings out a wish from the mental health professional 
to alleviate this uncomfortable feeling.  It is understandable that mental health 
staff—lay and professionals alike—are reluctant to require a patient who is depen-
dent on tobacco to forego its use upon admission to a psychiatric treatment facility. 
It appears counter-intuitive to require persons who suffer symptoms of a mental ill-
ness to stop smoking when they enter a treatment facility for worsened symptoms.11 
A smoker often assigns a meaning to his or her smoking that sometimes only be-
comes apparent after an attempt is made to stop smoking.12  With the loss of smoking, 
a smoker may experience a feeling of loss similar to losing a reliable friend.  For a 
smoker with a psychiatric illness, smoking may even take on a unique magical or 
ritualistic significance.13  Thus, mental health professionals anticipate a variety of 
concerns that result from restricting patients with mental illness from tobacco while 
treating their illness.  
[hereinafter Technical Report on Smoking] available at http://www.nasmd.org/medicaid_mental/
docs/ NASMHPD_Technical_Report_ on_Smoking_Policy.pdf.    
8. Kagan et al., supra note 7, at 476.  But see Wayne R. Smith & Brian L. Grant, Effects of a Smoking Ban on 
a General Hospital Psychiatric Service, 40 Hosp. & Cmty. Psychiatry 497, 502 (1989) (“[D]espite dire 
predictions, the smoking ban produced fewer negative effects and more positive effects than both 
medical and nursing staff had anticipated.”).
9. See Kagan et al., supra note 7, at 474.
10. See id. See generally James B. Lohr & Kristen Flynn, Smoking & Schizophrenia, 8 Schizophrenia Res. 
93 (1992) (discussing smoking behavior and schizophrenia, explanations for and against whether 
smoking may alleviate or exacerbate symptoms, and medication side effects).  One often stated 
hypothetical explanation for heavy smoking by individuals with schizophrenia is that the “increase in 
dopamine release induced by smoking may be helpful in alleviating some schizophrenic symptomatology” 
and “chronic smoking behavior may help alleviate schizophrenic symptoms.”  Id. at 99.
11. The term mental illness has been defined as:
  [C]linically significant behavioral or psychological syndrome or pattern that occurs in an 
individual and that is associated with present distress (e.g., a painful symptom) or disability 
(i.e., impairment in one or more important areas of functioning) or with significantly 
increased risk of suffering death, pain, disability, or an important loss of freedom.
 Am. Psychiatric Ass’n, Diagnostic and Statistical Manual of Mental Disorders: DSM-
IV-TR xxxi (4th ed. text rev. 2000) [hereinafter DSM-IV-TR].  
12. See John S. Tamerin, The Psychodynamics of Quitting Smoking in a Group, 129 Am. J. Psychiatry 589, 
590–93 (1972).
13. Cf. Ann Marie Carosella et al., Smoking Attitudes, Beliefs, and Readiness to Change Among Acute and Long 
Term Care Inpatients with Psychiatric Diagnoses, 24 Addictive Behav. 331, 340 (1999).
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The mental health treatment culture is steeped in the belief that tobacco must be 
available within psychiatric treatment settings to avoid aggression.  Yet, careful ex-
amination of tobacco use and its removal from psychiatric treatment settings shows 
that tobacco’s presence within the treatment milieu plays a pivotal role in the level of 
aggression within these milieus.  As more public psychiatric treatment facilities ban 
tobacco use from their grounds, long-held beliefs that removing tobacco will create 
undue stress and even aggression are fading.  Clinical observations and data from 
these public psychiatric facilities demonstrate decreased patient aggression and de-
creased staff injuries when tobacco is removed.14  This new data concerning the 
effect of tobacco use on the course and treatment of mental illness, provides a com-
pelling argument for removing all tobacco from psychiatric treatment facilities. 
Historically, the mental health community has needed more persuasive argu-
ments than the well-known detrimental health effects of tobacco to justify removing 
tobacco from psychiatric treatment settings.15  Concerns based on the unique nature 
of mental illness and the special circumstances surrounding psychiatric hospitaliza-
tion are voiced by mental health professionals who advocate for maintaining tobacco 
within treatment facilities.16  This paper will present data showing that keeping to-
bacco available in state psychiatric hospitals can be detrimental to the treatment of 
mental illness and has a high potential for creating harm in the form of increased 
aggression.  This paper will also present information showing that those who suffer 
with mental illness do not experience worse symptoms or more suffering without ac-
cess to tobacco while in the hospital setting.  Thus, there is now a persuasive argument 
for removing tobacco that also speaks to the empathic mental health professional. 
Removing tobacco from the state psychiatric treatment facility creates a less aggres-
sion-prone treatment milieu and facilitates a higher likelihood for more effective 
treatment.  Despite these compelling arguments, however, efforts to keep tobacco 
available within psychiatric treatment facilities present serious hurdles to successful 
implementation of a tobacco ban.17  Accordingly, support of the legislature is vital to 
ensure that a tobacco ban is successfully levied.
This article examines the controversy surrounding smoking in psychiatric insti-
tutions.  Section II will acquaint the reader with the history of tobacco use within 
14. See Anthony G. Hempel et al., Effect of a Total Smoking Ban in a Maximum Security Psychiatric Hospital, 
20 Behav. Sci. & L. 507 (2002); John Quinn et al., Results of the Conversion to a Tobacco-Free Environment 
in a State Psychiatric Hospital, 27 Admin. & Pol’y Mental Health 451 (2000).
15. See Center for Disease Control, History of the Surgeon General ’s Reports on Smoking and Health, Feb. 28, 
2007, http://www.cdc.gov/tobacco/data_statistics?Sgr/History.htm; Center for Disease Control, 
Cigarette Smoking—Attributable Mortality and Years of Potential Life Lost—United States, 1990, Aug. 27, 
1993, http://www.cdc.gov/MMWR/preview/mmwrhtml/00021441.htm.
16. See S. Health and Family Security Comm., S.F. 108, 2005 (Minn. 2005) (failed to advance) (advocating 
for patients in mental health and chemical dependence facilities to smoke); Senate Highlights, Senate 
Briefly (Minn. S. Publications, St. Paul, MN), Feb. 25, 2005, at 9.  
17. Quinn et al., supra note 14, at 519.  “An unexpected observation was the difficulty the hospital employees 
had with the ban on nicotine. This resistance culminated in a group of workers marching outside one of 
the hospitals in protest of the ban. This was a short-lived protest, but staff acceptance of the ban lagged 
behind patient acceptance.”  Id.  “[C]ontraband was typically brought in by staff . . . .”  Id. at 516.
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psychiatric hospitals.  Section III will present data on the prevalence of smoking by 
individuals with serious mental illness and chemical dependence and their vulnera-
bility to dependence on nicotine and the behavior of smoking.18  The mental illnesses 
discussed will include schizophrenia, mood disorders (including major depressive 
disorder), anxiety disorders (including panic disorder), and alcohol and drug depen-
dence.19  Section III will also address the effect of chronic tobacco smoking on 
patients’ health, including significantly shorter life expectancies, and the likelihood 
that smoking contributes to the intensity of mental illness symptoms such as anxiety 
and depression.  As background to the legal issues of Section V, smoking’s effects on 
medication dosages, medication side effects, and the movement disorder tardive dys-
kinesia are discussed. Section IV will discuss the effects of smoking abstinence on 
mental illness symptoms, as well as the observations of, and challenges faced by, 
public psychiatric facilities that have successfully removed tobacco from their prem-
ises. Section V will discuss Minnesota Statute section 246.0141, which, in January 
2004, mandated that all tobacco products be removed from the grounds of state op-
erated facilities for the treatment of mental illness.  The legal basis for this legislation 
will be presented through the cases Jarvis v. Levin and Price v. Sheppard, along with 
a civil case challenging this legislation.  Section VI concludes by arguing that legisla-
tive action is critical to protect the health and safety of our most vulnerable citizens. 
Historically, changes to smoking policies for public settings, and even for within 
medical facilities, have required regulatory or statutory action.  The public psychi-
atric treatment center is the final frontier for statutory action.  
II. HISTORY OF TOBACCO USE WITHIN STATE PSYCHIATRIC TREATMENT FACILITIES
Concerns over tobacco use within psychiatric hospitals have existed since the 
advent of American psychiatry.  The unpublished manuscripts of Samuel B. 
Woodward (1787–1850), a prominent psychiatric physician, contain observations of 
the effects of tobacco use on patients in psychiatric institutions during psychiatry’s 
early history, prior to the development of contemporary psychiatric medications.20 
Dr. Woodward was the first president of the American Psychiatric Association 
(“APA”) and the first superintendent of the Worcester State Hospital in Massachusetts, 
from 1832 until 1846.  Dr. Woodward’s 1834 paper, The Use of Tobacco as a Luxury, 
describes his observations of the effects of tobacco on patients’ health: “My own ex-
perience in the practice of my profession has brought under my observation many 
cases in which serious indisposition has been kept up for a long time by tobacco in its 
various forms, all of which symptoms have generally subsided by discontinuing the 
drug.”21 
18. Tamerin, supra note 12.
19. Each mental disorder will be discussed infra Part III.B.
20. Jeffrey L. Geller & Neil Kaye, Smoking in Psychiatric Hospitals: A Historical View of a Hot Topic, 41 Hosp. 
& Community Psychiatry 12, 1349–50 (1990).  
21. Id. at 1349.
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Later, in a separate paper, Two Communications on the Use of Tobacco, Dr. 
Woodward describes the addictive nature of tobacco: “It also produces a fascination 
or excitement analogous to that produced by opium and alcohol, which makes the 
consumer a slave to the habit, keeping him under factitious excitement when used, 
and when withdrawn subjects him to suffering and distress, little less horrible than 
delirium tremens.”22 
Dr. Woodward’s concerns about tobacco led him to attempt a ban on its use at 
Worcester State Hospital in 1833.  This was likely the earliest documented attempt 
to ban tobacco use in a state psychiatric facility, and like similar contemporary ef-
forts, it met stiff resistance from the staff.  In The Use of Tobacco as a Luxury, Dr. 
Woodward wrote: 
Well knowing that tobacco was liable to be very improperly used by the in-
sane, an early effort was made to exclude it from the hospital.  In order to 
effect this, the attendants on the patients were requested to relinquish the 
habit, and a regulation was adopted, requiring that the use of it be prohibited 
wholly in the Institution . . . and the regulation is not adhered to with as 
much strictness as would be desirable.23 
As has been observed in modern state psychiatric facilities, the successful tobacco-
free facility requires that everyone forego its use while on facility property.24  Because 
some staff resisted Dr. Woodward’s efforts, tobacco was once again permitted inside 
the institution and has remained there since.  Although efforts to make the Worcester 
State Hospital a smoke-free facility resumed in 1990, patient smoking privileges are 
currently available inside a secure area of the hospital and on its grounds.25  
Until the more stringent JCAHO policy of 1992, many psychiatric hospitals and 
psychiatric units within general hospitals utilized exemptions to allow smoking in-
doors.  Even the Minnesota Clean Indoor Air Act of 1975,26 which eventually 
mandated that hospital and clinic buildings be smoke-free by 1987, made exemptions 
for smoking indoors within psychiatric facilities “pursuant to a policy that identified 
circumstances in which the prohibition of smoking would interfere with the treat-
ment of persons recovering from chemical dependence or mental illness.”27  Thus, as 
22. Id.
23. Id. at 1350.
24. If patients are to be restricted from smoking then staff and visitors must also be restricted.  See discussion 
infra Part IV.C–D.  Brief ly, this avoids problems of unfairness and focusing policy toward patients only 
within a facility rather than the creation of a tobacco-free milieu.  This also avoids patients experiencing 
cues to smoke by observing others smoking which can incite agitation and resentment.  
25. E-mail from Cynthia Carrero, Director of Nursing, Worcester State Hospital, to Maureen Hackett, 
M.D., Adjunct Associate Professor, University of Minnesota (Dec. 10, 2007) (on file with author).
26. Minn. Clean Indoor Air Act, Minn. Stat. § 144.411–417 (2005).
27. See Minn. Clean Indoor Air Act, Minn. Stat. § 144.414(3)(b) (2005).  The statute allowed for the 
following exemption:
  [S]moking by patients in a locked psychiatric unit may be allowed in a separated well-
ventilated area in the unit under a policy established by the administrator of the program 
that allows the treating physician to approve smoking if, in the opinion of the treating 
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the medical field removed tobacco from clinical treatment settings, psychiatry kept 
tobacco accessible, supported by policy and statutory exemptions.  
III.  PREVALENCE AND EFFECTS OF SMOKING ON MENTAL ILLNESS SYMPTOMS   
 AND TREATMENT  
Studies conducted in the United States and abroad document that individuals 
suffering with mental illness smoke tobacco and depend on nicotine at twice the rate 
of the general population.  Reasons for such high smoking rates are complex and 
elusive.  The general adult population smoking rate in the United States has dimin-
ished from 42% in 1965 to 24.7% in 1997 to 20.8% in early 2006.28  Karen Lasser, 
M.D., conducted an analysis of the National Co-Morbidity Survey, a United States 
population based prevalence study from 1990–1992, and concluded that persons with 
a current mental disorder consumed 44.3% of the tobacco sold in the United States.29 
Heavy smoking (more than twenty-five cigarettes per day) was rare among persons 
with no history of mental illness—only 10% were heavy smokers.  In addition, this 
study showed that persons with mental illness quit tobacco for more than one year in 
substantial numbers, but at a lower rate than the general population (37% versus 
42.5%).  This study also found that abstainers from illicit drugs and alcohol were 
able to quit tobacco use at nearly the same rate as the general population.  This phe-
nomenon challenges the notion that one need treat addictions sequentially rather 
than concurrently, and it is receiving more recognition within the chemical depen-
dence treatment community.30  A 2001 survey examining the co-occurrence of 
nicotine dependence and psychiatric disorders in 43,093 adults found the highest 
prevalence of nicotine dependence (as distinct from smoking status) among individ-
uals with a current alcohol or drug use disorder—34.5% and 52.4%, respectively.31 
This study by Bridget Grant, Ph.D., examined tobacco use in all its forms and spec-
ified tobacco dependence as distinct from cigarette smoking, which was used by 
other studies and may or may not indicate nicotine dependence.  Grant’s study con-
physician, the benefits to be gained in obtaining patient cooperation with treatment 
outweigh the negative impacts of smoking. 
 Minn. Clean Indoor Air Act, Minn. Stat. § 144.414(3)(b) (2005).
28. Centers for Disease Control and Prevention, Prevalence of Current Smoking Among Adults Aged 18 Years 
and Over: United States 1997–June 2006 (2006), available at http://www.cdc.gov/nchs/data/nhis/
earlyrelease/200612_08.pdf.  
29. See Karen Lasser et al., Smoking and Mental Illness: A Population-Based Prevalence Study, 284 JAMA 
2606, 2608 (2000).
30. See Butler Ctr. for Research and Learning, Hazelden Inst., Research Update: Nicotine 
Addiction Associated with Use of Alcohol and Other Drugs (1999) (“While the methodologies 
vary considerably, the research conducted to date generally supports the notion that smoking cessation 
does not threaten sobriety or recovery from other addictions, and in fact, may even enhance it.” (citation 
omitted)).  
31. Bridget F. Grant et al., Nicotine Dependence and Psychiatric Disorders in the United States: Results from the 
National Epidemiologic Survey on Alcohol and Related Conditions, 61 Archives of Gen. Psychiatry 
1107, 1111 (2004).
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firmed the earlier work by Lasser, concluding that nicotine dependent individuals 
with a co-morbid psychiatric disorder comprise 7.1% of the population, yet consume 
34.2% of cigarettes in the United States.32
A. Increased Mortality of Mental Illness and Chemical Dependence Due to Smoking 
New data indicates that patients with serious mental illness experience higher 
rates of premature death than was previously suspected.  Three studies published in 
2006 observed that patients treated for serious mental illness in public psychiatric 
facilities experienced earlier death than the general population of the same demo-
graphic region.33  Causes of death included unnatural or external causes, such as 
suicide and accidents, and natural causes, such as heart, cerebrovascular and respira-
tory diseases, and cancer.34  One study, which was conducted in the Tuscany region 
of Italy, found a three-fold higher overall mortality for psychiatric patients compared 
with that of the general population.35  A study conducted on patients in Ohio calcu-
lated a standardized mortality ratio of 3.2 to 1.0 (ratio of deceased psychiatric patients 
to deceased members of the general population) and concluded that heart disease 
(21%) and suicide (18%) were the leading causes of death.36  This Ohio study calcu-
lated a mean of thirty-two years of potential life lost, with the leading cause being 
suicide, culminating in 41.7 years of potential life lost.37  All three studies concluded 
that mental health care must integrate primary medical care, including specific risk 
reductions through lifestyle modifications, such as obesity reduction and smoking 
cessation.38  Other contributors to this shorter life expectancy in patients treated 
within the public sector include treatment with the newer or second generation an-
tipsychotic medications, substance abuse, and the symptoms of mental illness.39
A British study, which followed a community sample for thirteen years and ex-
amined the circumstances of death in patients with schizophrenia, concluded that 
32. See id.
33. See Debora Meloni et al., Mortality Among Discharged Psychiatric Patients in Florence, Italy, 57 
Psychiatric Services 10, 1474–81 (2006) (reporting the mortality and cause of death determined for 
all patients admitted during 1987 to psychiatric units in Florence, Italy); Brian J. Miller et al., Mortality 
and Medical Comorbidity Among Patients with Serious Mental Illness, 57 Psychiatric Services 10, 
1482–87 (2006) (studying patients admitted to an Ohio public mental health hospital between 1998–
2000); Craig W. Colton & Ronald W. Manderscheid, Congruencies in Increased Mortality Rates, Years of 
Potential Life Lost, and Causes of Death Among Public Mental Health Clients in Eight States, Preventing 
Chronic Disease, 3 Preventing Chronic Disease 2 (2006) (comparing the mortality of public mental 
health clients in eight states with the mortality rates of the general populations of those eight states).
34. See Meloni et al., supra note 33; Miller et al., supra note 33; Colton & Manderscheid, supra note 33.
35. See Meloni et al., supra note 33.
36. See Miller et al., supra note 33.
37. See id.
38. See Meloni et al., supra note 33; Miller et al., supra note 33; Colton & Manderscheid, supra note 33.  
39. See Donald C. Goff et al., Medical Morbidity and Mortality in Schizophrenia: Guidelines for Psychiatrists, 
66 J. Clin. Psychiatry 183, 190–91 (2005).
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most of the excess natural mortality of this community sample was due to cigarette 
smoking.40  Excess natural mortality means death due to a medical cause, as distinct 
from an external or unnatural cause, such as an accident or suicide.  This study ex-
trapolated the illness, and the risk of those illnesses caused by smoking, and 
determined that smoking was the main contributor to the excess premature deaths. 
Unfortunately, patients with mental illness are also exposed to medications that can 
cause health problems.  Patients treated with second generation antipsychotic medi-
cations are at increased risk of experiencing metabolic changes leading to type 2 
diabetes mellitus.41  The most frequent cause of death in patients with diabetes is 
cardiovascular disease.42  A recent systematic review of studies assessing the associa-
tion between active smoking and the incidence of type 2 diabetes concluded that 
active smoking is associated with type 2 diabetes and that active smoking may be a 
seperate independent risk factor for developing type 2 diabetes.43  While most pa-
tients’ emotional stability depends upon their use of antipsychotic medications, thus 
exposing them to the risk of developing diabetes and the subsequent effects of dia-
betes, the additional risk of developing diabetes from smoking is preventable.  Type 
2 diabetes is an illness that occurs along a spectrum of severity and its negative ef-
fects on body systems, such as the cardiovascular and cerebrovascular systems, are 
worsened by tobacco use.  Though mentally ill patients may depend on medications 
that cause them to develop type 2 diabetes, avoiding tobacco use and implementing a 
healthy lifestyle can mitigate the long-term medical complications of the diabetes.  
40. Steve Brown, Hazel Inskip & Brian Barraclough, Causes of the Excess Mortality of Schizophrenia, 177 
Brit. J. of Psychiatry 212, 212 (2000).  Schizophrenia is a disorder that lasts for at least six months 
and includes at least one month of two or more active-phase symptoms categorized into two broad 
categories: 1) Positive symptoms which ref lect an excess or distortion of normal function, delusions, 
hallucinations, and disorganized speech or grossly disorganized behavior; 2) Negative symptoms which 
ref lect diminution or loss of normal function; restricted emotional expression, f luency, and productivity 
of thought and speech, and the initiation of goal-directed behavior.  These signs and symptoms are 
associated with marked social or occupational dysfunction.  DSM-IV-TR, supra note 11, at 298–99.
41. Thomson Healthcare Inc., Physicians’ Desk Reference 1868 (62d ed. 2008) [hereinafter 
Physicians’ Desk Reference].  For Zyprexa, “epidemiological studies suggest an increased risk of 
treatment emergent hyperglycemia-related adverse events in patients treated with the atypical 
antipsychotics.”  Id.  
42. See Lowell Schmeltz & J. Larry Jameson, Hot Topic: Intensive Insulin Therapy Prevents CVD in Type 1 
DM, Harrison’s Principles of Internal Medicine 17 (Dec. 28, 2005), available at http://www.
accessmedicine.com/updatesContent.aspx?aID=1000682&searchStr=Lowell+Schmeltz+ (online update 
to Chapter 323 Diabetes Mellitus of the 17th edition of Harrison’s Principles of Internal 
Medicine).  “Individuals with diabetes have a [two]-fold increase in all-cause mortality compared to 
non-diabetics . . . and a shortened life expectance by approximately [ten] years.  Cardiovascular disease 
(CVD) is the reported cause of death in 65% of individuals with diabetes in the United States.”  Id.; see 
also Joel C. Kleinman et al., Mortality Among Diabetics in a National Sample, 128 Am. J. Epidemiology 
389 (1988).  
43. Carole Willi et al., Active Smoking and the Risk of Type 2 Diabetes: A Systematic Review and Meta-analysis, 
298 JAMA 2654, 2654 (2007).
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Alcohol and drug dependence often occur simultaneously with mental illness, 
especially with mood and anxiety disorders.44  Early mortality also occurs in associa-
tion with alcohol and drug dependence.  Richard Hurt, M.D., of the Mayo Clinic, 
studied specific causes of early death in patients suffering with alcohol and other 
drug dependencies, examining all patients enrolled in a chemical dependence treat-
ment program spanning ten years and then following their mortality at twenty 
years.45  The observed mortality at twenty years significantly exceeded the expected 
mortality: 48.1% in the chemically dependent patients versus 18.5% in the general 
population, matched for the same community demographics.  The majority of deaths 
were tobacco related at 50.9%, while 34.1% were alcohol related.  Dr. Hurt concluded 
that nicotine dependence treatment is imperative in this high risk group.  
B. Smoking and Nicotine Dependence and Associated Mental Illness Symptoms 
 1. Schizophrenia and Tobacco Use
Historically, patients with symptoms of psychosis, particularly those diagnosed 
with schizophrenia, smoke at the highest rates when compared to the general popu-
lation, and even when compared with people experiencing other forms of mental 
illness.46  This is true even after controlling for confounding factors such as institu-
tionalization and alcohol or drug use.47  A hypothesis that has permeated the mental 
health community, one that is sometimes used to justify keeping tobacco available 
within psychiatric facilities, is that nicotine’s effect on the central nervous system al-
leviates the symptoms associated with schizophrenia.48  Other explanations for this 
44. Bridget F. Grant et al., Prevalence and Co-occurrence of Substance Use Disorders and Independent Mood and 
Anxiety Disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions, 61 
Archives Gen. Psychiatry 807, 807 (2004).
45. See Richard D. Hurt et al., Mortality Following Inpatient Addictions Treatment: Role of Tobacco Use in a 
Community-Based Cohort, 275 JAMA 1097 (1996).  
46. See Technical Report on Smoking, supra note 7, at 3.  The estimated smoking prevalence for people 
with mental illness: major depression (50–60%); anxiety disorder (45–60%); schizophrenia (65–85%). 
Id.
47. See Jose de Leon & Francisco J. Diaz, A Meta-analysis of Worldwide Studies Demonstrates an Association 
Between Schizophrenia and Tobacco Smoking Behaviors, 76 Schizophrenia Res. 135 (2005) (finding that 
schizophrenia patients had a higher prevalence of ever smoking than the general population); John R. 
Hughes et al., Prevalence of Smoking Among Psychiatric Outpatients, 143 Am. J. Psychiatry 993 (1986) 
(finding that the prevalence of smoking among psychiatric outpatients was significantly higher than 
among either local or national population-based samples, even when controlling for age, sex, marital 
status, socioeconomic status, alcohol use, and institutionalization); S. Levander et al., Nicotine Use and 
Its Correlates in Patients with Psychosis, 116 ACTA Psychiatrica Scandinavica 27 (2007) (finding 
that nicotine use in psychotic patients was twice as common as in the general population and only a few 
nicotine users had started after the onset of psychoses). 
48. Alexander H. Glassman, Cigarette Smoking: Implications for Psychiatric Illness, 150 Am. J. Psychiatry 
546, 550 (1993) (“Although some authors have suggested that this high rate of cigarette smoking is an 
effort to reduce drug-induced side effects, it seems reasonable to consider the possibility that this very 
intense use of nicotine by chronic schizophrenic patients serves some more directly therapeutic 
purpose.”).
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high rate of smoking focus on the side effects of antipsychotic medications, including 
body movement dysfunctions previously thought to be countered by nicotine’s ef-
fects.49  Another reason cited to keep tobacco available is its alleged remediation of 
cognitive impairments that are inherent to schizophrenia.  It is thought that nicotine 
may improve cognition; therefore patients with schizophrenia are nicotine users to 
self-medicate their slowed cognitive functioning.50  Until recently, a common fear 
among mental health professionals was that patients with schizophrenia might expe-
rience worsened symptoms of psychosis upon abstaining from tobacco use. 
Recent studies conducted in Scotland, Spain, and Sweden examined the rela-
tionship between tobacco use (smoking or chewing snuff) and schizophrenia.51  The 
Scottish and Swedish studies found that most patients with schizophrenia started 
smoking in their teens (median age seventeen).52  Furthermore, the Scottish study 
found that smoking preceded the onset of schizophrenia in approximately 90% of the 
patients.53  The Scottish and Spanish studies documented poor long-term outcomes 
in those patients with schizophrenia who were the heaviest tobacco users.54  The 
Scottish study evaluated the smoking habits and tobacco cessation rates in all pa-
tients diagnosed with schizophrenia who lived within one geographic region, had 
similar socioeconomic backgrounds, and were treated within the same healthcare 
system in southwest Scotland.55  Smoking rates within this group were higher than 
that of the local general population, at 58% versus 28%.56  Interestingly, this rate is 
lower than rates observed by many older studies of schizophrenia, which ranged 
from 70–90%.57  One explanation for this is the distribution of patients studied: the 
contemporary study observed both outpatient and hospital settings while the earlier 
studies likely only observed institutionalized patients.58  Another possible explana-
tion for the lower rates of smoking among patients observed in the contemporary 
49. See A.G. Awad & L.N.P. Voruganti, Neuroleptic Dysphoria: Revisiting the Concept 50 Years Later, 111 
ACTA Psychiatrica Scandinavica 6, 11 (2005); S. Silversti et al., Does Nicotine Affect D2 Receptor 
Upregulation? A Case Control Study, 109 ACTA Psychiatrica Scandinavica 313, 313(2004).
50. Kristi A. Sacco et al., Effects of Cigarette Smoking on Spatial Working Memory and Attentional Deficits in 
Schizophrenia: Involvement of Nicotine Receptor Mechanisms, 62 Archives of General Psychiatry 649, 
649 (2005).  Untoward cardiovascular effects limit nicotine’s clinical use as a cognitive enhancer. 
Research on other substances that act as nicotine agonists and potential cognitive enhancers is beyond 
the scope of this paper.
51. Ciara Kelly & Robin G. McCreadie, Smoking Habits, Current Symptoms, and Premorbid Characteristics of 
Schizophrenic Patients in Nithsdale, Scotland, 156 Am. J. Psychiatry 1751, 1752 (1999); M. Carmen 
Aguilar et al., Nicotine Dependence and Symptoms in Schizophrenia: Naturalistic Study of Complex 
Interactions, 186 Brit. J. Psychiatry 215, 215 (2005); Levander et al., supra note 47, at 27–28.
52. Kelly & McCreadie, supra note 51, at 1752; Levander et al., supra note 47, at 30–31.
53. Kelly & McCreadie, supra note 51, at 1755.
54. Id. at 1756; Aguilar et al., supra note 51, at 220.
55. Kelly & McCreadie, supra note 51, at 1752.
56. Id. at 1755.
57. See DSM-IV-TR, supra note 11, at 266; Hughes et al., supra note 47, at 993.
58. Kelly & McCreadie, supra note 51, at 1752.
110
SMOKE-FREE STATE PSYCHIATRIC FACILITY GROUNDS
studies is that patients with mental illness are simply mirroring the trend in the gen-
eral population and quitting smoking in greater numbers.
In general, patients hospitalized for schizophrenia smoke at higher rates than 
other patients with schizophrenia.59  This is consistent with the findings of the 
Scottish study, which found that patients with schizophrenia who smoked required 
more psychiatric services, more hospital admissions and more frequently received 
medication treatment via intramuscular injections of antipsychotic medications than 
non-smoking patients.60  The Spanish study also found that the patients most heavily 
dependent on nicotine had the highest proportion of hospital admissions.61  Both the 
Spanish study and the Scottish study concluded that smoking signified a worsened 
course of illness and that the patients with schizophrenia who smoked or used snuff 
did so more heavily (the equivalent of more than twenty-five cigarettes per day) than 
the general population of smokers.62  The Scottish study also demonstrated that pa-
tients with schizophrenia can stop smoking successfully.63  The study found that 
females with schizophrenia quit smoking at the same rate as that seen in the local 
general population.64  In addition, smoking cessation programs for patients with 
schizophrenia and the clinical experience of tobacco-free psychiatric hospitals have 
shown that abstinence from tobacco does not worsen or cause relapses in symptoms 
of psychosis.65  
A Swedish study by Levander examined the self-medication hypothesis with 
regard to cognition and the side effects of medication.66  The study prospectively 
examined patients diagnosed with schizophrenia or schizophrenia-related psychosis 
yearly over five years to assess their level of nicotine intake in the form of cigarettes 
or snuff.  The study also assessed the severity of illness, treatment rendered, medica-
tion side effects, and cognitive impairments.  This five year study found no support 
for a self-medication hypothesis as there were no significant differences found be-
tween those with schizophrenia that used tobacco and those that did not use tobacco. 
Patients who smoked did not exhibit improved cognitive functioning or less medica-
tion side-effects than nonsmokers.  Levander concluded that patients with psychosis 
“fail to desist” from using tobacco rather than use tobacco for a beneficial neuro-
chemical effect.  Levander based this opinion on his observation that all but a few 
59. J. De Leon et al., Schizophrenia and Smoking: An Epidemiological Survey in a State Hospital, 152 Am. J. 
Psychiatry 453, 453 (1995).
60. Kelly & McCreadie, supra note 51, at 1751. 
61. Aguilar et al., supra note 51, at 218.
62. Id. at 217; Kelly & McCreadie, supra note 51, at 1755.
63. Kelly & McCreadie, supra note 51, at 1756.
64. Id. at 1752.
65. See Douglas M. Ziedonis & Tony P. George, Schizophrenia and Nicotine Use: Report of a Pilot Smoking 
Cessation Program and Review of Neurobiological and Clinical Issues, 23 Schizophrenia Bull. 247, 251 
(1997); Monihan et al., supra note 5, at 7; Quinn et al., supra note 14, at 452 (finding a decrease in acts 
of aggression following enactment of the no smoking policy).
66. Levander et al., supra note 47, at 28.
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patients began using tobacco an average of eight years before the onset of their 
schizophrenic illness, and the patients did not experience significant positive benefits 
from using tobacco.67  Levander opined that the task of the healthcare system is a 
practical one: to find better methods to help patients with schizophrenia stop using 
tobacco rather than to identify complex mechanisms underlying their use of to-
bacco. 
 2. Smoking’s Effect on Anxiety and Depressive Symptoms
Studies investigating the relationship between smoking and mood disorders have 
focused on anxiety disorders and major depression, as well as sub-clinical depressive 
symptoms.68  One study noted that “[b]oth anxiety and depression are thought to 
play a role in the initiation, maintenance and cessation of smoking behaviors.”69 
Regarding anxiety, studies have found an association between smoking and the pres-
ence of anxiety disorders.70  A 1986 study by Dorothy Hatsukami, M.D., of the 
University of Minnesota, found 47% of psychiatric outpatients diagnosed as having 
67. Id. at 30–31.  The Levander study found the following:
  The most parsimonious interpretation of our findings is that patients with schizophrenia 
and other psychotic disorders are nicotine dependent because they have started to smoke 
already in their teens, well before onset of psychosis. It is a reasonable assumption that the 
psychotic illness interferes with their ability to stop smoking (failure to desist rather than 
pressure to persist) . . . .
 Id.
68. See DSM-IV-TR, supra note 11, at 349–56.  Depressive symptoms are classified according to symptom 
intensity, length, or associated symptoms.  Id. at 349.  
  The essential features of Major Depressive Episode is a period of at least 2 weeks during 
which there is either depressed mood or the loss of interest or pleasure in nearly all 
activities. In children or adolescents the mood may be irritable rather than sad.  The 
individual must also experience at least four additional symptoms drawn from a list that 
includes changes in appetite or weight, sleep, and psychomotor activity; decreased energy; 
feelings of worthlessness or guilt; difficulty thinking, concentrating or making decisions; 
or recurrent thoughts of death or suicidal ideation plans or attempts . . . a symptom must 
either be newly present or must have clearly worsened compared with the person’s pre-
episode status.  
 Id. at 429.  Diagnoses of anxiety disorders include: panic attack, agoraphobia, panic disorder with and 
without agoraphobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, social 
phobia, acute stress disorder, obsessive-compulsive disorder, anxiety disorder due to general medical 
condition, substance-induced anxiety disorder, and anxiety disorder not otherwise specified. 
69. Holly E. R. Morrell & Lee M. Cohen, Cigarette Smoking, Anxiety and Depression, 28 J. Psychopathology 
& Behav. Assessment 4, 283 (2006). 
70. See DSM-IV-TR, supra note 11, at 429.  Anxious mood or anxiety is not a formal diagnosis but a 
symptom description that may qualify as a formal anxiety disorder as listed in DSM-IV.  Id.; see also 
Denise B. Kandel et al., Psychiatric Disorders Associated with Substance Use Among Children and Adolescents: 
Findings from the Methods for the Epidemiology of Child and Adolescent Mental Disorders (MECA) Study, J. 
Abnormal Child Psychol. 121, 132 (1997); J. Himle, B.A. Thyer & D.J. Fischer, Prevalence of 
Smoking Among Anxious Outpatients, 1 Phobia Pract. Res. J. 25, 25–31 (1998).
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an anxiety disorder used tobacco.71  Two hypotheses have been proposed to account 
for the association between anxiety and smoking.  One hypothesis is that having 
anxiety increases the risk of smoking due to a variety of factors, including calming 
effects of smoking, facilitation of social interactions, and peer pressure.72  A second 
hypothesis is that smoking causes anxiety due to its effects on respiratory functioning 
and the stimulation effects of nicotine.73  Because smoking initiation usually occurs 
in adolescence and young adulthood, prospective studies of children and adolescents 
can look specifically at whether smoking contributes to the initiation of anxiety or 
whether having an anxiety disorder increases the likelihood of becoming a regular 
smoker.  In fact, prospective studies of adolescents have shown that smoking may 
actually predispose individuals to develop anxiety disorders.74  When adolescents 
were studied for six years from ages sixteen to twenty-two years, Johnson found that 
heavy smoking was associated with higher rates of agoraphobia, generalized anxiety 
disorder, and panic disorder in early adulthood.75  The inverse association was not 
found; anxiety disorders during adolescence did not result in higher rates of chronic 
cigarette smoking during early adulthood.  A five-year study of adults by Breslau and 
Klein found that smoking initiation increased the risk for subsequent panic attacks 
by at least three-fold.  However, having a pre-existing panic disorder was not associ-
ated with increased incidence of daily smoking.76  The relationship between anxiety 
and smoking is likely a complex interplay of biological and behavioral factors.  The 
biological factors are complex and likely include the stimulating effects of nicotine,77 
71. James R. Hughes et al., Prevalence of Smoking Among Psychiatric Outpatients, 143 Am. J. Psychiatry 
993, 995 (1986).
72. H. Sonntag et al., Are Social Fears and DSM-IV Social Anxiety Disorder Associated with Smoking and 
Nicotine Dependence in Adolescents and Young Adults?, 15 Eur. Psychiatry 67, 73 (2000).  
73. Naomi Breslau & Donald F. Klein, Smoking and Panic Attacks: An Epidemiologic Investigation, 56 
Archives Gen. Psychiatry 1141, 1146 (1999); Steven C. Dilsaver, Nicotine and Panic Attacks, 144 Am. 
J. Psychiatry 1245, 1245 (1987).
74. Jeffrey G. Johnson et al., Association Between Cigarette Smoking and Anxiety Disorders During Adolescence 
and Early Adulthood, 284 JAMA 2348, 2350 (2000); Barbara Isensee et al., Smoking Increases the Risk of 
Panic: Findings from a Prospective Community Study, 60 Archives of Gen. Psychiatry 692, 698 
(2003). 
75. See Johnson et al., supra note 74.  “The essential feature of Agoraphobia is anxiety about being in places 
or situations from which escape might be difficult (or embarrassing) or in which help may not be 
available in the event of having a Panic Attack or panic-like symptoms.”  DSM-IV-TR, supra note 11, at 
432.  “The essential features of generalized anxiety disorder is excessive anxiety and worry . . . occurring 
more days than not for a period of at least six months about a number of events or activities.”  Id. at 476. 
Generalized anxiety disorder is also characterized by difficulty controlling the excessive worry, 
accompanied by at least three symptoms such as difficulty concentrating, restlessness, and being easily 
fatigued.  Id.  “Panic disorder is characterized by reoccurring, unexpected panic attacks.  A panic attack 
is a discrete episode of intense fear or discomfort” with four or more accompanying symptoms such as 
pounding heart, sweating, trembling, shortness of breath, or smothering sensations.  Id. at 432.
76. Breslau & Klein, supra note 73, at 1145; see also Isensee et al., supra note 74, at 698 (“Preexisting panic 
did not show any association with later onset of smoking or nicotine dependence.”).
77. Daniel S. McGehee et al., Cellular and Synaptic Effects of Nicotine, in Medication Treatments for 
Nicotine Dependence 25, 27 (Tony P. George ed., 2007). 
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the effects of carbon monoxide (which displaces oxygen that is bound to the hemo-
globin of red blood cells) that can be measured in smokers’ breath,78 and the 
pulmonary effects of smoking (which creates higher levels of carbon dioxide in 
chronic smokers with chronic obstructive pulmonary disease).  Carbon dioxide ad-
ministration is a reliable means to induce panic attacks and is used in mental health 
research.79  Thus, individuals who smoke raise their levels of anxiety due to bio-
chemical effects, and then continue to use the behavior of smoking (focused and 
controlled breathing) to lower their anxiety.  The result is likely an escalating cycle 
of anxious mood. 
As stated earlier, mental health professionals advocate for the availability of to-
bacco as a means for patients to calm themselves.  The actual behavior or activity of 
smoking and the context in which it is done may provide a brief and limited calming 
effect.  A recent study by Beckham investigated the effects of nicotinized and deni-
cotinized cigarettes on craving, mood, and symptoms of posttraumatic stress disorder 
(“PTSD”).80  The study found that smoking either type of cigarette decreased crav-
ings for smoking and decreased negative mood and symptoms of PTSD, but these 
ameliorative effects of having smoked a cigarette were short-lived.  The study con-
cluded that the context and non-pharmacologic effects—i.e., the behavior intrinsic to 
smoking, such as controlled breathing and focused attention to a limited stimu-
lus—are important variables.  These variables brief ly reduce craving and relieve 
negative moods, particularly in smokers with PTSD who are exposed to stressful 
conditions.  In contrast to this brief diminishment of negative mood through smoking 
even denicotinized cigarettes, long-term smoking abstinence has been shown to de-
crease anxiety over a four week period.81  Though the behaviors intrinsic to smoking, 
such as controlled breathing, appear to provide brief relief from negative moods, 
these effects are short-lived and likely even detrimental in the long-term when com-
pared to the more lasting benefits of stopping altogether or never initiating smoking 
at all.  Nonetheless, the behaviors associated with smoking need to be creatively ad-
dressed to assist patients with smoking cessation.  Such behaviors include the 
78. See Arthur C. Guyton & John E. Hall, Textbook of Medical Physiology 509–10 (Elsevier Saunders 
ed., 11th ed. 2005); Karl Fagerström, Assessment of the Smoker Who Wants to Quit, 56 Monaldi Archives 
for Chest Disease 2, at 124–27 (2001) (“The most important factors to assess are probably motivation, 
dependency and CO [carbon monoxide] in expired air.”).  
79. Marlies A. van Duinen et al., CO2 Challenge Results in Hypothalamic-Pituitary-Adrenal Activation in 
Healthy Volunteers, 19 J. Psychopharmacology 3, at 243–47 (2005) (“The 35% CO2 challenge is 
known to induce symptoms of a panic attack both in panic disorder (PD) patients and healthy 
volunteers.”).  
80. Jean C. Beckham et al., The Effects of Cigarette Smoking on Script-Driven Imagery in Smokers With and 
Without Posttraumatic Stress Disorder, 32 Addict Behav. 2900, 2900 (2007).
81. Robert West & Peter Hajek, What Happens to Anxiety Levels on Giving Up Smoking, 154 Am. J. 
Psychiatry 1589, 1589 (1997).
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assignment of meaning to smoking by the smoker, social interactions, focused and 
limited stimulus attention, and controlled breathing exercises.82  
Studies of depressive symptoms and major depressive disorders conclude that 
there is a highly significant relationship between smoking and major depression, and 
that each has been found to be predictive of the other.83  At least one study has raised 
the possibility that smoking initiation leads to, or is causally linked to, the develop-
ment of depressive symptoms.  Over five years, Drs. Wu and Anthony studied 
adolescents who began smoking regularly and found that those who smoked had a 
modestly increased risk of depressive symptoms.  In this same study, those adoles-
cents with antecedent depressed moods did not have a higher associated risk of later 
cigarette smoking.84  
Kenneth S. Kendler, M.D., in a study of 1,566 female monozygotic (or identical) 
twins, proposed a genetic vulnerability to both major depression and to heavy nico-
tine consumption.85  His study was also the first to document a strong association 
between smoking and future episodes of major depression.  Kendler concluded that a 
genetic factor was common to both major depression and to smoking, and that this 
genetic factor caused both.  
Patients with depression, as with other mental disorders, appear vulnerable to 
dependence on tobacco.  According to Naomi Breslau, those individuals with active 
major depression are more likely to progress to daily smoking compared to patients 
with major depression in remission.86  Having a history of depression also affects 
smoking cessation program completion.  According to a study by Alexander H. 
Glassman, M.D., individuals with a history of depression who attempt to stop 
smoking have higher attrition rates from cessation programs.87  
Smoking has been linked to suicidal thoughts and behaviors, as well as to suicide 
itself.  The association between suicide and smoking has been found in epidemio-
logic studies of non-psychiatric subpopulations of physicians and nurses.88  While 
researchers caution against interpreting this data to conclude that smoking is an in-
dependent risk factor for suicide, it is noteworthy that smoking was found to be a 
predictor of suicide in a Finnish study of depressed individuals.  Antti Tanskanen, 
82. David Olivier, Dan I. Lubman & Richard Fraser, Tobacco Smoking Within Psychiatric Inpatient Settings: 
A Biopsychosocial Perspective, 41 Austl. & N.Z. J. Psychiatry 572 (2007). 
83. Tamerin, supra note 12, at 590.
84. Li-Tzy Wu & James C. Anthony, Tobacco Smoking and Depressed Mood in Late Childhood and Early 
Adolescence, 89 Am. J. Pub. Health 1837, 1983 (1999).
85. Kenneth S. Kendler et al., Smoking and Major Depression: A Causal Analysis, 50 Archives Gen. 
Psychiatry 36, 36 (1993). 
86. Naomi Breslau, Scott P. Novak & Ronald C. Kessler, Psychiatric Disorders and Stages of Smoking, 55 
Biologic Psychiatry 69, 69 (2004).
87. Alexander H. Glassman et al., Smoking, Smoking Cessation, and Major Depression, 264 JAMA 1546, 
1546 (1990).  
88. David Hemenway, Sara J. Solnick & Graham A. Colditz, Smoking and Suicide Among Nurses, 83 Am. J. 
Pub. Health  249, 250 (1993).
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M.D., Ph.D., surveyed all 1,744 psychiatric patients evaluated in one year at a hos-
pital in eastern Finland and found the probability of at least one previous suicide 
attempt to be two times higher among current smokers with severe depression than 
among nonsmokers with severe depression.89  Smokers with depression were also 
found to have a 43% greater risk of suicidal thoughts than nonsmokers even after 
controlling for age, sex, marital status, education, income level, employment status, 
psychiatric diagnosis, alcohol drinking pattern, and level of depression.  
 3.  Antipsychotic Medication and Smoking
The combustion byproducts of smoke, called polycyclic aromatic hydrocarbons, 
stimulate or induce a smoker’s liver to increase the metabolism and clearance of cer-
tain antipsychotic medications.90  This increased metabolism then lowers the parent 
or active medication compound experienced by the smoker, requiring higher doses to 
achieve the same therapeutic effect.  Antipsychotic medications are used to treat an 
array of mental illness symptoms common to many diagnostic categories.  Symptoms 
include psychosis, mania, and agitation.  Many of the side effects of these medica-
tions are dose dependent, so taking higher doses exposes patients to untoward effects, 
such as fatigue, and life-threatening side effects, such as seizures.91  Increased me-
tabolism means more metabolites, which can increase side effects.  Many studies 
have demonstrated that among patients treated for schizophrenia and mood disor-
ders, smokers require higher doses of certain antipsychotic and antidepressant 
medication.92  The Levander study did not demonstrate higher doses of medications 
for smokers, but half of the male patients chewed tobacco, which creates no smoke-
related hydrocarbons to affect medication metabolism.  
 4. Tardive Dyskinesia
Tardive dyskinesia, an involuntary movement disorder, is a known and irrevers-
ible side effect associated with maintenance or long-term treatment with conventional 
antipsychotic medications, such as haloperidol.  Tardive dyskinesia is characterized 
by involuntary muscle movements, such as chewing or licking movements, and in-
89. Antti Tanskanen et al., Smoking and Suicidality Among Psychiatric Patients, 155 Am. J. Psychiatry 129, 
129 (1998).
90. Hiral D. Desai, Julia Seabolt & Michael W. Jann, Smoking in Patients Receiving Psychotropic Medications: 
A Pharmacokinetic Perspective, 15 CNS Drugs 469, 470 (2001).
91. Jose De Leon, Scott C. Armstrong & Kelly L. Cozza, The Dosing of Atypical Antipsychotics, 46 
Psychosomatics 262, 265–66 (2005).
92. See Physicians’ Desk Reference, supra note 41, at 1867; Desai et al., supra note 90, at 474–75. 
Zyprexa, a trade name for olanzapine, is a second generation or atypical antipsychotic medication: 
“Olanzapine clearance is about 40% higher in smokers than in nonsmokers although dosage modifications 
are not routinely recommended.”  Id.  Examples of antidepressants whose metabolism is affected by 
smoking are: amitriptyline, clomipramine, and imipramine f luvoxamine.  Antipsychotics medications 
include: clozapine, olanzapine, haloperidal, and chlropromazine.  See Aage Tverdal et al., Mortality in 
Relation to Smoking History 13 Years’ Follow-Up of 68,000 Norwegian Men and Women 35–49 Years, 46 J. 
Clinical Epidemiology 475 (1993).
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volves muscles of the extremities or trunk along with muscle movements for 
swallowing and speech production.  The rate at which patients develop tardive dys-
kinesia increases with the length of treatment with antipsychotic medications.93  
Spontaneous dyskinesias, which are clinically indistinguishable from tardive 
dyskinesia, have occurred in the absence of antipsychotic medications more fre-
quently in men who smoke than in men who do not smoke.94  Agneta Nilsson studied 
a general population of 559 healthy Swedish men of age fifty-five to assess abnormal 
involuntary movements and risk factors associated with these dyskinesias.  The study 
found that an individual without any known risk factor (a nonsmoker without antip-
sychotic medication exposure) had a 5.3% probability of abnormal involuntary 
movements.  Smoking twenty or more cigarettes per day increased the probability to 
18.7%, exposure to antipsychotic medications increased the probability to 29.7%, and 
a high risk individual with both antipsychotic exposure and more than twenty ciga-
rettes daily had a probability of dyskinesia as high as 63.6%.  Greater frequencies of 
dyskinesias have been observed in patients who smoked and received antipsychotic 
medications than in patients who did not smoke but received the same medica-
tions.95  
The permanent and disfiguring nature of tardive dyskinesia, and its potential 
occurrence as an effect of antipsychotic medication treatment, provided the legal 
justification in the state of Minnesota for classifying involuntary treatment of pa-
tients with antipsychotic medications as a form of “intrusive treatment,” a category 
that requires a court petition to force the medications on individuals who have been 
found legally incompetent and unwilling to take them voluntarily.96  
In Jarvis v. Levine, the Supreme Court of Minnesota relied on its decision in 
Price v. Sheppard in finding that forced antipsychotic medications is an intrusive 
treatment because of the potential for developing permanent abnormal body move-
ments of tardive dyskinesia, as well as the potential for other side effects.97  A petition 
for “intrusive treatment” with antipsychotic medications was deemed necessary when 
patients who refused such treatment were found to be incompetent and in need of 
treatment.98  In Price, the court concluded that the state must use the least restrictive 
means available when intrusive treatments are proposed in order to mitigate the im-
93.  John M. Kane & Anil K. Malhotra, Treatments of Psychiatric Disorders, Psychopharmacology 
of Schizophrenia and Other Psychotic Disorders, 1038 (Glen O. Gabbard ed., 3d ed. 2001). 
94. Agneta Nilsson et al., Cigarette Smoking Is Associated with Abnormal Involuntary Movements in the General 
Male Population: A Study of Men Born in 1933, Biological Psychiatry, 717 (1997).
95. Ramzy Yassa et al., Nicotine Exposure and Tardive Dyskinesia, 22 Biological Psychiatry 67, 67 (1987). 
High dose neuroleptics also called antipsychotics are known to mask the abnormal movements of tardive 
dyskinesia, which become clinically apparent upon medication withdrawal or reduction.  Some studies 
finding no increased tardive dyskinesia associated with smoking also show that the patients that smoke 
took higher doses of antipsychotic medication.  The high dose of antipsychotic likely masked the clinical 
signs of these abnormal muscle movements which generally occur in the face and mouth area.  Id.
96. See Price v. Sheppard, 239 N.W.2d 905 (Minn. 1976).
97. See Jarvis v. Levine, 418 N.W.2d 139, 143–46 (Minn. 1988) (citing Price, 239 N.W.2d 905). 
98. Price, 239 N.W.2d at 913.
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pact on patients’ rights.99  In other words, the court required that other less restrictive 
alternatives be attempted to treat the patient’s symptoms before resorting to intrusive 
treatment. 
IV. TOBACCO ABSTINENCE, MENTAL ILLNESS, AND PUBLIC PSYCHIATRIC   
 TREATMENT FACILITIES
A. Tobacco, Nicotine and Addiction, and the Phenomenon of Craving
Nicotine, the main addictive component of tobacco, is a psychoactive substance 
with stimulant and positive reinforcement properties.  Nicotine’s effects on the brain’s 
receptors are not completely understood.  Nicotine acts on neurotransmitters within 
the central nervous system that are also targeted by psychotropic medications, opioid 
medications, and even cocaine.100  Nicotine acts on centers within the brain by in-
creasing levels of many neurotransmitters including beta-endorphins, dopamine, and 
norepinephrine.  Nicotine receptors, which are stimulated by nicotine, modulate 
major neurotransmitters that are also targeted by antidepressants and anti-anxiety 
medications.101  Although the effects of nicotine-induced alteration of neurotrans-
mitter levels are not completely understood, it is known that individuals build up a 
tolerance to nicotine and experience significant withdrawal symptoms when its use is 
abruptly stopped.102  Individuals with mental illness may be more sensitive to the ef-
fects of nicotine, or more sensitive to the dysphoria experienced when nicotine levels 
drop.  Adequate nicotine replacement, as a component of tobacco cessation programs 
and within tobacco-free facilities, is important to avoid abrupt nicotine withdrawal. 
Nicotine reaches the brain within ten seconds of inhalation and stimulates dop-
amine release within the brain center, called the nucleus accumbens, likely through 
activation of nicotine acetylcholine receptors.103  Dopamine release caused by nico-
tine use is thought to create the addictive quality of nicotine, similar to dopamine 
release caused by other psychostimulants, such as cocaine.  In fact, the subjective 
feeling of craving, which is stimulated by cuing an addicted person with reminders of 
their addicted substance, is thought to involve dopamine release within the brain.104 
According to Steven D. LaRowe, “a common feature of many definitions of craving 
is that it is a subjective state of desire with motivational properties that have an im-
99. Id.
100. See David J. Scott et al., Smoking Modulation of µ-opioid and Dopamine D2 Receptor-Mediated 
Neurotransmission in Humans, 2007 Neuropsychopharmacology 450.
101. See K.O. Haustein, S. Haffner & B.G. Woodcock, A Review of the Pharmacological and Psychopharmacological 
Aspects of Smoking and Smoking Cessation in Psychiatric Patients, 40 Int’l J. Clinical Pharmacology & 
Therapeutics 404 (2002). 
102. Beckham et al., supra note 80, at 2900.
103. Id.
104. See Steven D. LaRowe et al., Reactivity to Nicotine Cues over Repeated Cue Reactivity Sessions, 32 
Addictive Behaviors 2888, 2896 (2007), available at http://www.sciencedirect.com.
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portant role in the procurement and consumption of drugs.”105  Measures of craving 
and cue reactivity have been used to predict relapse and to assess treatment of addic-
tions.  It is craving that fuels or pushes an addicted person to use, and feelings of 
craving are monitored as signs of active addiction.  Smokers commonly report ex-
treme cravings to smoke when they see other individuals smoke or when they 
experience reminders of smoking, such as watching a smoking scene in a movie. 
When an addicted person is maximally cued, but their ability to use is denied or only 
partially relieved, then feelings of tension increase. 
Psychiatric facility staff and patients describe feeling intimidated by the intensity 
of patients’ drive to smoke and are fearful of the consequences of interfering with 
that desire.106  This is a logical explanation for why partial smoking bans are consid-
ered more difficult to enforce and ultimately do not create the less aggressive 
environment than that experienced with total smoking bans.107  To avoid engen-
dering cravings and the resulting frustrations and aggression, treatment facilities 
need to remove cues to use tobacco by extending the ban to the entire facility grounds, 
and to all patients, staff, and visitors.  
B. Tobacco-Free Settings: Tobacco Abstinence and Mental Illness Symptoms
Despite the difficulty that individuals with mental illness experience with 
smoking cessation, studies have demonstrated that acute psychiatric symptoms do 
not worsen following admission to a smoke-free psychiatric facility.108  Predictions of 
increased assaultive behaviors and discharges against medical advice were unfounded. 
A review of findings from twenty-six international studies on the efficacy of smoking 
bans in inpatient psychiatric settings found that staff generally anticipated more 
smoking cessation-related problems than actually occurred.109  Despite a few case 
reports,110 no increases in aggression, use of seclusion, discharges against medical 
advice, or increased use of as-needed medications for agitation were documented fol-
lowing smoking bans, especially where bans were for the entire facility premises and 
105. Id. at 2889 (citations omitted).
106. Technical Reports on Smoking, supra note 7, at 7.
107. See, e.g., Grant T. Harris et al., Effects of a Tobacco Ban on Long-Term Psychiatric Patients, 34 J. Behavioral 
Health Services & Res. 43, 44 (2007) (“Where total tobacco proscriptions (banning all tobacco 
products) have been instituted, common experiences include greater ease of enforcing tobacco prohibition 
than in partial bans, elimination of environmental tobacco smoke, no rise in aggression and gradual 
acceptance of the ban.”). 
108. See Cedric M. Smith et al., Obligatory Cessation of Smoking by Psychiatric Inpatients, 50 Psychiatric 
Services 91, 94 (1999); Ellen Haller, et al., Impact of a Smoking Ban on a Locked Psychiatric Unit, 57 J. 
Clinical Psychiatry 329, 332 (1996).
109. Sharon Lawn & Rene Pols, Smoking Bans in Psychiatric Inpatient Setting, 39 Austl. and N.Z. J. of 
Psychiatry 866, 866 (2005); Judith J. Prochaska et al., How Prepared Are Psychiatry Residents for 
Treating Nicotine Dependence?, 29 Acad. Psychiatry 256, 257 (2005).
110. See Michael Greenman & Thomas McClellan, Negative Effects of a Smoking Ban on an Inpatient Psychiatry 
Service, 42 Hospital and Community Psychiatry 408 (1991).
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not partial (e.g., indoor ban only).111  Although nearly all published studies have 
documented the absence of specific mental health problems from abrupt abstinence 
in smoke-free acute psychiatric facilities, shortcomings have been noted in the con-
sistent application of medical interventions for nicotine dependence.  To increase 
patient compliance with mental health treatment and engage them in the process of 
attaining long-term smoking cessation, psychiatric treatment must address patients’ 
nicotine dependence during their abrupt abstinence in tobacco-free settings.112  
C. Public Psychiatric Facilities
 1. Different Tobacco Policies and Stated Reasons for Such
Public or state hospitals provide long-term treatment to patients with chronic 
and severe mental illness, usually as a result of the state’s civil commitment process. 
Many of these facilities continue to allow tobacco use within the treatment setting. 
A 2006 survey of state mental health facilities by the National Association of State 
Mental Health Program Directors (“NASMHPD”) indicated that more than half of 
the 235 state-run public psychiatric facilities, which treat more than 50,000 patients 
at any given time, allow patients access to tobacco.113  Reasons listed for continued 
access to tobacco included using tobacco to decrease agitation, to de-escalate situa-
tions of conflict, and to reward patient compliance with staff.  Concerns regarding 
institution of tobacco-free status included resistance and opposition from staff mem-
bers who smoke and staff members’ fears of patients’ reactions, of patient rights 
advocates’ reactions, and of change in general.  This same survey found that 41% of 
the 158 facilities that responded to the survey prohibited tobacco use on their facility 
grounds.  The most commonly cited motivators for transitioning the facilities to to-
bacco-free included the promotion of healthier lifestyles and a cleaner environment, 
the provision of more time for active treatment, improved group therapy attendance, 
fewer incidences of fire danger, and compliance with state law.  Respondents that 
removed tobacco reported a decrease in behavioral problems related to smoking, de-
creased violence, and increased staff satisfaction subsequent to implementation of 
tobacco bans.  The conclusions of studies and reports of state facilities that have 
banned tobacco from their grounds strongly suggest that the successful implementa-
tion of tobacco bans and the avoidance of problems are dependent on successfully 
preventing patient access to tobacco.114  
 2. Aggression and Tobacco Removal
In 1998, North Texas State Hospital in Wichita Falls, Texas was one of the first 
state hospitals in the United States to convert to tobacco-free status.  North Texas 
111. Harris et al., supra note 107. 
112. See generally Prochaska et al., supra note 109 (addressing a need to train psychiatry residents in treating 
tobacco dependence).
113. Technical Reports on Smoking, supra note 7, at 6–7.
114. See Hempel et al., supra note 14; Quinn et al., supra note 14.
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State Hospital measured incidents of physical and verbal aggression and compared 
the results for the month prior to the conversion to the second month following the 
conversion.115  This study controlled for raters by using the same behavior analysts 
before and after the conversion and quantifying aggressive behaviors using the Overt 
Aggression Scale.116  Aggressive behaviors are categorized as verbal or physical. 
Verbal aggression ranges from mild to severe and includes angry shouting, yelling 
personal insults, cursing, and verbal threats.  Physical aggression includes aggression 
against objects, self, or other people.  Physical aggression ranges from causing no 
injury or minor injury to causing severe injury.  It includes slamming doors, throwing 
objects, kicking and breaking objects, causing self-harm, and finally hurting or at-
tempting to hurt others by pushing, grabbing, or hitting.  The findings were startling, 
showing a significant drop in the number of aggressive events by patients when to-
bacco was removed from the premises.  Incidents of verbal aggression decreased by 
45% while incidents of physical aggression decreased by 50%, from 266 incidents to 
133 incidents.  The researchers postulated that aggression was higher when tobacco 
was available because of the unequal distribution of tobacco.  Their review of injury 
reports pertaining to the period when smoking still occurred showed that numerous 
injuries were a result of a patient without cigarettes becoming intimidating or as-
saultive with staff or other patients in an attempt to get cigarettes, or as a result of 
confrontations triggered by staff imposing smoking restrictions on patients for 
smoking at inappropriate times or in inappropriate places.  This author’s inquiries 
with North Texas State Hospital found that the incidents of aggression continued to 
decrease every year, resulting in a significant decrease in staff injury rates for four 
consecutive years.  This garnered the hospital the Top Texas State Agency Safety 
Award for four consecutive years.117 
Tobacco’s presence in a treatment milieu is weaved into the fabric of interper-
sonal interactions, even for non-smoking patients.  Non-smoking patients witness 
and experience negative effects of tobacco within the hospital milieu.  A 1999 survey 
of 199 non-smoking patients in nine long-term state hospitals in three states revealed 
that, on a daily basis, 21% had witnessed staff use cigarettes to coerce and manipu-
late patients and 26% had witnessed patients threaten or coerce each other regarding 
cigarette-related issues.  Almost half of the patients reported being bothered by other 
patients’ smoking, with one-third of non-smoking patients reporting that they were 
too intimidated to request the smokers stop.118  Data from the California Department 
115. Quinn et al., supra note 14.
116. See generally Stuart C. Yudofsky et al., The Overt Aggression Scale for the Objective Rating of Verbal and 
Physical Aggression, 143 Am J. Psychiatry 35–39 (1986).
117. E-mail and telephone communication between Joel Inman, study author, North Texas State Hospital, 
and Gerald McLain, Chief Information Officer, North Texas State Hospital, to author (January 2003 
& January 2008) (e-mail on file with author).  
118. Technical Reports on Smoking, supra note 7, at 7.
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of Mental Health’s forensic facilities showed that the actual timing of violent epi-
sodes correlated with periods before and after smoke breaks.119
D. Creating Tobacco-Free Public Psychiatric Hospitals
 1. Arguing Decreased Aggression to Overcome Resistance to Change 
The NASMHPD technical report on smoking policy states that the overall 
goals of recovery from illness and wellness should be emphasized as the best moti-
vator for converting to smoke-free facilities.  The report recommends that such 
conversion should focus on broader change within the treatment milieu rather than 
the simple ban of tobacco.  This change should encompass a healthy lifestyle, with 
increased attention to smoking cessation efforts, as well as other supportive interven-
tions, such as increased physical and social activities to replace the interactions that 
patients experience with smoke breaks.120
Despite the support of sound medical knowledge and the experience of facilities 
with successful implementations, significant difficulties persist for facilities at-
tempting to convert to smoke-free status.  For example, the California Department 
of Mental Health encountered so much resistance from staff members and their 
unions as recently as 2006, that individual facilities have not been able to implement 
smoking bans.  In fact, the forensic facilities continue to allow indoor smoking.121 
The medical director for a California public psychiatric institution stated at the 
NASMHPD’s 2006 meeting that successful conversion of individual facilities was 
not likely to occur in the absence of a state policy requiring tobacco bans for all fa-
cilities.  Further, he postulated that a tobacco ban policy would likely gain acceptance 
if it emphasized the goals of improving patient and staff safety, rather than im-
proving health.122  This statement is indicative of the long-held notion that a more 
compelling argument to advocate banning tobacco use from psychiatric treatment 
facilities is one that emphasizes benefits beyond mere improved health.  Arguing for 
change based on decreasing aggression and improving the safety of the therapeutic 
milieu offers a separate and more compelling reason to withhold tobacco within the 
public psychiatric treatment setting.  Improved safety is measurable, can be experi-
enced within a short time frame, and decreases harm to patients and staff in their 
daily life within the psychiatric treatment facility.  
119. Id.
120. Id. at 23–32.
121. Id. at 19.  A forensic state psychiatric facility is a facility for the evaluation and treatment of individuals 
with criminal charges admitted before and/or following the adjudication of their criminal charges. 
These facilities require a more secure environment and are generally considered to have more dangerous 
patients.  
122. Technical Reports on Smoking, supra note 7, at 19.
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 2. Staff ’s Resistance to Tobacco Removal
In order to have a truly smoke-free facility and experience the benefits of the 
improved therapeutic milieu, staff members must cooperate and provide effective 
enforcement of smoking bans.123  However, mental health staff members who in-
teract daily with patients who are dependent upon tobacco may be compromised in 
their own ability to support or enforce smoking bans.  As noted earlier, the craving 
experienced by patients may intimidate staff.  In addition, staff members may them-
selves be smokers, and therefore reluctant to embrace decreased access to tobacco 
while on the job.  The rates of smoking among treatment staff in mental health and 
substance abuse facilities and programs appear higher than the general population, 
with approximately 30% to 40% of staff identified as smokers, compared with 22% 
of the general population.124  Mental health staff are likely reluctant to lose their 
ability to barter the use of tobacco in negotiating behavioral issues with patients. 
Although overt use of tobacco as a behavioral modifier borders on and may even ex-
emplify unethical treatment, one third of facilities that permit smoking and responded 
to the NASMHPD survey reported using tobacco as a behavioral incentive by linking 
smoking access to privilege status.125  Staff support for smoke-free psychiatric treat-
ment settings in facilities that are smoke-free indicates that many staff members 
become convinced of the benefits only after the change has successfully occurred. 
Furthermore, staff who smoke anticipate and perceive more smoking-related prob-
lems than staff nonsmokers.  This gap in perception does not decrease with the 
successful implementation of a no smoking policy.126  Since staff members’ coopera-
tion is crucial to the success of these policies, overcoming their resistance is an 
essential part of establishing a tobacco-free psychiatric treatment milieu.  Involving 
staff and other interested parties—including patients, patient advocates, patients’ 
families, and even union representatives—in the planning and implementation pro-
cess is one method to facilitate successful change.127
V.  LEGISLATING SMOKE-FREE PUBLIC PSYCHIATRIC TREATMENT FACILITIES
A. An Ethical Debate: Statutory Law Versus Patient Rights
The medical profession has long subscribed to a body of ethical standards devel-
oped primarily for the benefit of the patient.  The Principles of Medical Ethics, 
adopted by the American Medical Association, recognizes the responsibility of phy-
sicians to patients first and foremost.  For example, Principle I states that “[a] 
physician shall be dedicated to providing competent medical care, with compassion 
123. Harris et al., supra note 104, at 44.
124. Technical Reports on Smoking, supra note 7, at 4.
125. Id. at 7.
126. Smith & Grant, supra note 8, at 501.
127. See Technical Reports on Smoking, supra note 7, at 16–17.
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and respect for human dignity and rights.”128  Principle III states that “[a] physician 
shall respect the law and also recognize a responsibility to seek changes in those re-
quirements which are contrary to the best interest of the patient.”129  These principles 
are not laws, but the standards of conduct that define the essentials of honorable 
behavior within the medical profession.130  
While respect for patient rights and respect for patient autonomy are funda-
mental guiding principles of ethical medical care, the ability to smoke within a 
treatment setting does not qualify as a fundamental right because granting permis-
sion to smoke does not meet the principle threshold of the physician’s duty to provide 
competent medical care.  Physicians do not intervene in all patient behavior that is 
harmful, but tobacco use within the psychiatric treatment setting not only allows ac-
cess to behavior that is harmful to the patient, but also negatively affects the overall 
treatment milieu.  Advocacy for patients’ right to make autonomous decisions re-
garding their personal behavior or even decisions regarding their medical treatment 
holds sway when the behavior or decision involves choices that are not directly and 
detrimentally affected by patients’ mental illness or chemical dependence symptoms. 
For example, patients in public facilities for the treatment of mental illness have 
voting rights, may enter into civil contracts, such as a divorce or marriage, and may 
even make medical decisions when their ability to make such decisions is not im-
paired by the symptoms of their mental illness.  Patients’ autonomy and ability to 
make choices about using tobacco, however, are encumbered by their dependence on 
tobacco products and may be limited further by their mental illness symptoms, such 
as depression, anxiety, and psychosis.  The availability of tobacco does not provide an 
opportunity for true choice because, by definition, nicotine-dependent individuals 
experience a breakdown in their ability to control their use of nicotine, and they ex-
perience clinical distress related to this lack of control.  Given the overwhelming 
evidence of tobacco’s negative effects, as well as the increased vulnerability to nico-
tine dependence experienced by individuals suffering from mental illness, it is the 
opinion of this author that the medical and ethical duty of physicians to remove to-
bacco from the treatment setting outweighs any support for a patient’s right to use 
tobacco while in the treatment milieu.
B. The Need for Legislative Support in Making the Change to Smoke-Free  
Significant resistance to tobacco-free psychiatric treatment settings creates 
daunting barriers for administrators and medical practitioners to effectively establish 
tobacco-free environments.  Despite overwhelming evidence of negative health ef-
fects from tobacco and mounting evidence of tobacco’s additional harm within 
psychiatric treatment settings, robust resistance to change is expressed even by some 
128. Am. Med. Ass’n, Code of Medical Ethics: Current Opinions with Annotations, – 
(2008).
129. Id.
130. Id.
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psychiatrists.131  Unfortunately, the expression of these opinions creates more resis-
tance to change by others who look to physicians for leadership. 
Evidence of a historic lack of medical leadership to remove tobacco from inside 
medical treatment settings can be traced to the mandates that were necessary to 
make general medical hospitals and clinics smoke-free.  The passage of statutory law 
within Minnesota, via the Clean Indoor Air Act Amendment of 1987, and the nearly 
simultaneous national accreditation requirements of the JCAHO were necessary.132 
Those medical professionals who seek to change a medical setting’s smoking policy 
need to garner the assistance and enforcement power of a responsible administrative 
or legal agency.  Government intervention, through establishing new law, is the most 
effective and efficient way to accomplish a tobacco ban for public psychiatric treat-
ment facilities.  For example, while the North Texas State Hospital superintendent 
and other administrators chose to make their individual facility smoke-free, the 
Texas legislature’s cooperation was needed to defeat the opposition, which had sought 
legislative intervention to prevent this change.133  While the legislature in Texas 
simply protected the policy change made by administrators, the legislature in 
Minnesota actively passed law to remove tobacco from the grounds of all state oper-
ated regional treatment centers.134  This same Minnesota bill also removed the 
exemption from the Clean Indoor Air Act for smoking within facilities for the treat-
ment of mental illness and chemical dependence.135  
C. The State Legislature and the Public Psychiatric Treatment Facility 
Public psychiatric treatment facilities are primarily state funded and operated. 
Their operations are the responsibility of elected state officials who are ultimately 
responsible to the state’s citizens.  Thus, the general public has a direct interest in the 
treatment provided within public facilities.  A state legislature supports its state con-
stitution, and members of each state legislature swear or affirm to uphold their state 
constitution upon taking office.136  While each state’s constitution differs in its spe-
131. See Quinn et al., supra note 14; Minnesota House of Representatives, Session Weekly, Mar. 12, 2004, 
at 14, available at http://www.house.leg.state.mn.us/hinfo/swkly/2003-04/sw604.pdf#page=14(reporting 
on testimony given to the Minnesota House Health and Human Services Policy Committee on March 
8, 2004 for HF 2312, a bill intended to rescind 2003 legislation that removed tobacco from state 
operated treatment facilities).
132. Minn. Clean Indoor Air Act, Minn. Stat. § 144.414(3)(a) (1990) (“Smoking is prohibited in any area 
of a hospital, health care clinic, doctor’s office, or other health care-related facility other than a nursing 
home, boarding care facility, or licensed residential facility . . . .”).  The statute then allowed for 
exceptions within chemical dependence treatment programs or mental health programs.  Minn. Clean 
Indoor Air Act, Minn. Stat. § 144.414(3)(b) (1990).
133. Technical Reports on Smoking, supra note 7, at 15.
134. S. 1329, 2003–2004 Leg., 83rd Sess. (Minn. 2003); H.R. 1329, 2003–2004 Leg., 83rd Sess. (Minn. 
2003).
135. Id.
136. See, e.g., Minn. Const. art. IV, §8.
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cific wording, the general purpose or object of state government is expressed within 
its constitution. 
For example, Article 1, Section 1 of the Minnesota State Constitution describes 
the object of government as the following: “Government is instituted for the security, 
benefit and protection of the people in whom all political power is inherent, together 
with the right to alter, modify, or reform government whenever required by the public 
good.”137  Thus, the legislative process, which may set standards of practice within 
non-publicly funded and operated facilities, has an even greater interest in the opera-
tions of public psychiatric treatment facilities.  
Physicians who wish to make changes to the public psychiatric treatment setting 
may facilitate change from within the state operated institution system, or propose 
legislation that would have the state government mandate the desired change. 
Working from within a system is usually preferable as it avoids the need for new laws 
to regulate medical treatment.  Also, obtaining support for change from personnel 
within the system may be easier without the intrusion of a legal mandate.  However, 
the high resistance to change regarding tobacco access within public psychiatric set-
tings frequently necessitates garnering legislative support, either in the form of new 
law, or in the form of support by refusal to intervene and stop such a change.  That 
is, even when a new policy is supported by top-level administrators within the 
state-operated system, the legislature can be solicited to stop subsequent changes to 
that policy by policy opponents.
D. Legal Arguments for Enacting Statutory Laws to Ban Tobacco in Psychiatric  
 Treatment Settings
As discussed in Section III of this article, tobacco use contributes to the intensi-
fication of certain symptoms of mental illness, and it contributes to the development 
of negative side effects associated with the treatment of these illnesses.  It therefore 
follows that removing tobacco from psychiatric treatment settings is arguably one of 
the least intrusive treatment alternatives available.  Minnesota case law establishes a 
definition of intrusive treatment, as well as for the principle of least restrictive alter-
native.  In Price v. Sheppard, the conduct at issue was the administration of 
electroconvulsive therapy, without proper consent, on a minor who was under invol-
untary commitment at a state mental hospital.138  The Supreme Court of Minnesota 
held that future cases must obtain court consent to apply intrusive forms of treat-
ment.139  The court stated: 
The techniques generally available to treat psychological disorders range in 
degree of severity from the least intrusive forms such as milieu therapy (be-
havior changes produced by manipulation of  the patient’s environment) and 
137. Minn. Const. art. I, § 1.
138. 239 N.W.2d 905.
139. Id. at 911.
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psychoanalysis to drug, aversion, or electroconvulsive therapy, and ultimately 
to psychosurgery.140 
Mentally ill patients who smoke may require higher doses of antipsychotic med-
ications.  Thus, these patients are at greater risk of failed medication treatment and 
of experiencing negative side effects, including the permanent side effect of tardive 
dyskinesia.  As demonstrated in the Scottish and Spanish studies, examined in 
Section III, Part B, those patients with schizophrenia who smoke experience worse 
symptoms, as evidenced by their increased hospitalizations and use of intramuscular 
antipsychotic medications.  Increased patient aggression has been shown to occur 
within treatment settings with tobacco available.  Thus, a higher potential for more 
intrusive treatments, such as seclusion and restraints, forced antipsychotic medica-
tion and even electroconvulsive therapy, exists when patients have access to tobacco 
within the psychiatric treatment milieu.  So, removing access to tobacco presents a 
less restrictive treatment alternative.  
Ultimately, if the treatment environment is improved by removing access to to-
bacco, one can argue that the tobacco-free public psychiatric facility is a less intrusive 
treatment setting, as well as a healthier one for patients, staff, and visitors.  This ar-
gument is supported by data showing lower patient aggression in tobacco-free 
treatment settings.  Lower patient aggression translates into less supplemental (fre-
quently forced) medication doses for aggressive events.  Additionally, without the 
metabolic effects of smoking on medications, lower requisite medication doses are 
possible during the hospital period, when patients’ symptoms are at their worst, thus 
exposing patients to concomitantly lower risks of adverse side effects.  Given all of 
this data, one can contend that public psychiatric facilities that maintain tobacco ac-
cess are exposing the state system to medical legal liability. 
Many patients are committed to these state facilities, without choice as to their 
placement, due to their civil commitment status.  If the presence of tobacco can be 
shown to expose even non-smoking patients to increased danger, then the potential 
exists for the state operated system to be liable for this increased risk should an ad-
verse event occur as a direct result of having tobacco available.  Additionally, those 
patients who are heavily dependent on tobacco may be incompetent to make deci-
sions regarding their psychiatric care and unable to weigh the detrimental effects of 
their smoking upon their mental illness treatment.  For example, patients treated 
with high doses of antipsychotic medication who also suffer life-threatening side ef-
fects may not be able to appreciate the detrimental impact smoking has on the dose, 
on the side effects of the medications, and on their symptoms of  mental illness. 
Having tobacco available for patients who are particularly vulnerable to using heavy 
amounts and experiencing detrimental effects to their health is another potential 
medical legal liability for a public psychiatric facility.
140. Id.
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E. Minnesota Legislative Initiatives
An examination of specific legislation passed in Minnesota illustrates the diffi-
culty in establishing tobacco-free policy and, by extension, the necessity for legislation 
to enact such a measure.  In 1998, while this author served as the clinical director at 
the Minnesota Security Hospital, a high-security forensic institution, the hospital 
allowed smoking and tobacco chewing within the confines of courtyards open to the 
outdoors and highly visible from within the treatment units (for security purposes). 
Approximately twenty-five patients sent a petition requesting that tobacco be re-
moved from the entire hospital grounds so that they could successfully stop smoking 
by removing the cues and temptation for their smoking that were present when others 
smoked.  The petition was sent to the hospital administrator, who replied: “Do not 
send this, when the state is involved in a lawsuit with tobacco companies.”141  Further 
action toward making Minnesota Security Hospital tobacco-free was immediately 
stopped. 
In 2002, this author took up the effort again, while in private practice, by writing 
letters to the Commissioner of Human Services.  By April 2003, the Minnesota 
Senate Health and Family Security Committee heard testimony on S.F. 1329, a bill 
to remove tobacco from the grounds of all state-operated facilities for the treatment 
of individuals with mental illness, chemical dependence, and developmental disabili-
ties, with extension also to facilities for treatment of sex offenders.142  The tobacco 
ban applied to the grounds and to all patients, staff, and visitors while on the 
state-operated grounds.  This author initiated the bill with the support of the 
Minnesota Medical Association and the Minnesota Psychiatric Society, and this 
author testified in support of it.  This author garnered the support of these medical 
associations through separate processes during the twelve months prior to testifying. 
Testimony included data on the detrimental effects of tobacco availability on the 
treatment milieu, as well as information indicating the absence of ill effects on pa-
tients with mental illness, or their treatment efforts, when tobacco is eliminated.  
The Minnesota State Operated Services is Minnesota’s title for its state organi-
zation that provides publicly funded treatment for mental illness and chemical 
dependence through outpatient and institutional settings.  The State Operated 
Services’ Chief Executive Officer (“CEO”) favored the initiative and also testified in 
support of the bill, but said that State Operated Services could neither advocate for it 
nor initiate it.  When a state senator asked why a law was required to enact a change 
that the CEO was supporting and could have been implemented without legislation 
supporting it, the CEO responded that the State Operated Services would not be 
able to change the facilities to tobacco-free status without a law to mandate such a 
change.  While the CEO clearly wanted such a change, it required support and lead-
ership from the Minnesota Commissioner of Human Services and the State Operated 
Services’ Medical Director, neither of whom responded to notification about the 
bill’s hearing.  Prior responses from the commissioner’s office indicated an unwill-
141. Conversation between Chief Executive Officer, St. Peter Regional Treatment, and author (1998). 
142. S. 1329, 2003 Leg. Sess. 83, Minn. Stat. § 144.414 (2007).
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ingness to convert Minnesota’s state facilities to tobacco-free.143  Thus, it was unlikely 
that the CEO could have garnered the support necessary to make such a change and 
a legal mandate would avoid the necessity of overcoming this resistance.  The state 
senate committee passed the bill.  Efforts were then made by this author to testify 
before the Minnesota House Health and Human Services Policy Committee in a 
hearing regarding state-operated services.  This was after the bill’s sponsor in the 
house was refused a formal hearing and an attempt by another sponsor was with-
drawn.  The bill was then debated within a separate ombudsman committee before it 
was signed into law by Governor Pawlenty in June 2003.144  
In January 2004, Minnesota Statute section 246.0141 went into effect.  During 
the following two legislative sessions, in 2004 and 2005, several psychiatrists testi-
fied in support of bills to repeal the law.145  Their testimony largely focused on the 
assertion that patients are under stress and that hospitalization is not the right time 
to force patients to stop smoking.  They also maintained that smoking was a source 
of pleasure for psychiatric patients, and that banning tobacco turned the staff into 
policemen.  While the testimony of these psychiatrists was emotionally compelling 
and expressed empathy for their patients’ desire to continue to smoke in a hospital 
setting, committee members were made aware, through this author’s testimony, that 
several private psychiatric facilities in Minnesota had been completely tobacco-free 
for over ten years, with no documentation of detrimental effects on patient care.  The 
competing arguments before the legislative committees were, on the one side, that 
denial of access to tobacco constituted harsh or even inhumane treatment, but, on 
the other side, that removing tobacco while treating for nicotine withdrawal causes 
no harm to patients and even improves treatment milieus.  The legislators voiced 
other compelling state interests, such as concern for patient safety from fire hazards 
and protecting patients from the general detrimental effects of tobacco.  The legisla-
tive initiative to repeal the newly enacted law in 2005 was sponsored by a state senator 
who advocated for patients’ right to smoke.  The majority of lawmakers, however, 
were in favor of continuing the tobacco ban, particularly since the Minnesota State 
Operated Services Director testified in 2005 that the policy was so successful that 
administration intended on keeping the ban in place even without a law mandating 
it.  
143. Letter from the Minn. Comm’r of Human Services addressed to author (Mar. 18, 2002) (on file with 
author).
144. Minn. Stat. § 144.414 (2007).
145. See S. Health and Family Security Comm., S.F. 108, 2005 (Minn. 2005); Senate Highlights, supra note 
16; see also Smoke-Free Facilities, 21 Session Weekly 6, 14 (Minn. House of Representatives Public 
Information, St. Paul, Minn.), Mar. 12, 2004, available at http://www.house.leg.state.mn.us/hinfo/
swkly/2003-04/sw604.pdf#page=14/.
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F.  The Legal Challenge to Minnesota Statute Section 246.0141
A civil complaint challenging the constitutionality of Minnesota Statute section 
246.0141 was brought by two patients of the Minnesota Security Hospital in 2003.146 
The plaintiffs alleged that the statute violated “their federal Constitutional rights 
under the First, Fourth, Fifth, Eighth, and Fourteenth Amendments, and their state 
Constitutional rights under Article I, sections 2, 7, and 10, and Article IV, sections 
17 and 19,” as well as their patients’ rights under the Minnesota Commitment 
stautes.147   The plaintiffs sought “declaratory and injunctive relief to redress these 
alleged violations.”148
The trial court dismissed the complaints with prejudice and stated the court’s 
findings of fact and conclusions of law in a memorandum.149  The court found “no 
constitutional right to smoke or to possess tobacco in a state treatment facility” and 
concluded that smoking is not a form of speech as the plaintiffs contended.150  The 
court also found that, as patients “in a secure treatment facility, [the] Plaintiffs have 
no reasonable expectation of privacy against search and seizure under the Fourth 
Amendment.”151  The plaintiffs alleged that the law was “intended as punitive condi-
tions directed solely at Plaintiff ’s class whom are private citizens with full citizenship 
confined as patients in a treatment facility.”152  The court stated: (1) the language of 
the statute is unambiguous and “applies to all persons on the grounds of a regional 
treatment center, not just to the patients”; (2) the “characterization of the legislation 
as ‘punitive’ is insufficient to state a claim under the Fifth Amendment”; and (3) the 
“legislation does not impose successive ‘punishment’ on them [the plaintiffs] for any 
criminal offense.”153  The court found that the Eighth Amendment right to be free of 
cruel and unusual punishment is not a valid claim “in this civil context,” as the plain-
tiffs were not claiming to be “imprisoned for a criminal offense.”154  The plaintiffs’ 
equal protection claims under the Fourteenth Amendment “fail[ed] to make the nec-
essary showing that they were treated differently than others similarly situated.”155 
Although the plaintiffs alleged that they were “treated differently than patients in 
other types of facilities” (such as nursing homes and veteran homes), the court did 
not find residents of these other facilities to be similarly situated to patients requiring 
146. Kruger v. Pawlenty, No. C2-03-10155, 2004 WL 5645011 (Minn. 2d Dist. Ct. Jan. 28, 2004) (dimissing 
plaintiffs’ complaint).
147. Id. at *2.
148. Id.
149. Id. at *1.
150. Id. at *2.
151. Id.
152. Summons at 6, Kruger v. Pawlenty, No. C2-03-10155 (Minn. 2d Dist. Ct. Sept. 24, 2003).
153. Kruger, 2004 WL 5645011, at *3.
154. Id.
155. Id.
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treatment within a state psychiatric treatment facility.156  The court found that all 
persons are subject “to the ban when they are on the premises of these facilities,” 
therefore “the statute [did] not distinguish between classes of people.”157 
As noted above, plaintiffs claimed that section 246.0141 “violat[ed] their due 
process rights under Article I, section 7, of the Minnesota Constitution.”158  The 
court found that neither a procedural due process nor a substantive due process right 
was violated.159  With regard to procedural due process, the court found that the 
plaintiffs failed to identify “a constitutionally protected property or liberty interest 
that [was] deprived by the legislation.”160  In other words, “smoking tobacco and pos-
session of tobacco are not constitutionally protected property or liberty interests” and 
the plaintiffs did not allege that they were “a suspect class or that smoking [was] a 
fundamental right.”161  With regard to the substantive due process claim, the court 
emphasized that “legislation will fail rational basis review only when it rests on 
grounds irrelevant to the achievement of a plausible government objective.”162  The 
court relied on this author’s testimony in determining that the statute met the ra-
tional basis test and was not enacted “for the purpose of punishing the patients, as 
was suggested by the plaintiffs.”163  Rather, the court determined through the legisla-
tive history that the “statute was enacted for the purpose of enhancing the health of 
individuals in regional treatment centers.”164  The statute passed the rational basis 
review because a plausible government objective, enhancing the health of individuals 
in treatment centers, was shown.165  The courts discussed the Fourteenth Amendment 
as providing that “no member of this state shall be disenfranchised or deprived of any 
of the rights or privileges secured to any citizen thereof, unless by the law of the land 
or the judgment of his peers.”166 
The Court of Appeals in Minnesota affirmed the decision of the Ramsey County 
District Court on February 1, 2005.167  One appellant argued that the district court 
had incorrectly relied on matters outside the pleadings when referring to testimony 
presented before the Senate Health and Family Security Committee of the 2003 
Legislative Session.  The Court of Appeals determined that the district court used 
156. Id.
157. Id.
158. Id.
159. Id.
160. Id. at *4.
161. Id.
162. Id. at *3. 
163. Id. at *4.
164. Id.
165. Id.
166. Id.
167. Kruger v. Pawlenty, No. A04-1041, 2005 WL 221929, at *6 (Minn. Ct. App. Feb. 1, 2005).
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this testimony in conducting its legal analysis specifically to determine the legislative 
intent behind enactment of the statute: “The [district] court concluded ‘the statute 
was enacted for the purpose of enhancing the health of individuals’ . . . .  We affirm 
the district court’s use of legislative history in making its legal determination.”168 
The Court of Appeals’ decision emphasized the importance of primary and rel-
evant psychiatric testimony provided to the legislative committee that was relied 
upon by the trial court.  Psychiatrists’ testimony in this instance was an essential 
component of the legislative process.
VI. CONCLUSION
Efforts to remove smoking from public psychiatric facilities have pitted argu-
ments for patients’ rights, pleasure, and limited purported therapeutic benefits against 
a growing body of clinical data documenting adverse health effects of smoking and 
public health data documenting the health and safety benefits of tobacco-free facili-
ties for patients and staff.  Opposition to such efforts from both inside and outside of 
facilities demonstrates that legislative action is a critical element to produce a neces-
sary change.  In Minnesota, psychiatric testimony during the legislative process 
proved necessary for the legislative initiative and was later relied upon by the district 
court in conducting its rational basis review of the legislation, specifically in deter-
mining whether there existed a plausible government objective.  The reliance upon 
pyschiatric testimony by the district court in Kruger v. Pawlenty was subsequently 
affirmed by the appellate court as procedurally correct and necessary.  While the 
legislature needs the psychiatric community to inform its decisions regarding the 
treatment of citizens committed to public treatment facilities, the psychiatric com-
munity should utilize the legislative process to successfully remove tobacco from 
psychiatric treatment facilities.  Together, the psychiatric community and state legis-
latures must work not only to bring about sweeping change, but also to thwart 
attempts to resist and rescind that change. 
168. Kruger, 2005 WL 221929, at *2.
